SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder TEL AVIV, Israel, March 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...

Axial Therapeutics CEO A. Stewart Campbell to Present at Microbiome Connect: USA 2022 WOBURN, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for...

Axial Therapeutics Expands Clinical Development Capabilities with Key Appointments - Clinical development operations focused on ongoing Phase 2b clinical trial of AB-2004 in autism; data anticipated in 2023 - - Team also supporting additional microbiome-based small molecule...